TAKEDA PHARMACEUTICAL CO LTD
TAKReported to SECin USCIK 0001395064Filings at SEC EDGAR
TAK is one of 2 listed share classes under this CIK; the filings below cover all of them.
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 62. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Duprey Lauren RusckowskiChief Transformation Officer | Open-market sell | $640,27934,535 shares | Sep 15, 2026 | Duprey Lauren RusckowskiChief Transformation Officer | $640,279 | Open-market sell | 34,535 | Sep 15, 2026 |
| Plump Andrew StewartPresident, R&D | Open-market sell | $2,148,372116,191 shares | Sep 3, 2026 | Plump Andrew StewartPresident, R&D | $2,148,372 | Open-market sell | 116,191 | Sep 3, 2026 |
| Plump Andrew StewartPresident, R&D | Open-market sell | $363,34719,651 shares | Aug 21, 2026 | Plump Andrew StewartPresident, R&D | $363,347 | Open-market sell | 19,651 | Aug 21, 2026 |
| Greenway Nicola Deidre PetalChief Human Resources Officer | Open-market sell | $235,11812,980 shares | Aug 19, 2026 | Greenway Nicola Deidre PetalChief Human Resources Officer | $235,118 | Open-market sell | 12,980 | Aug 19, 2026 |
| Farajallah Awny Samaan BotrosChief Medical Officer | Open-market sell | $239,50314,006 shares | Aug 12, 2026 | Farajallah Awny Samaan BotrosChief Medical Officer | $239,503 | Open-market sell | 14,006 | Aug 12, 2026 |
Lobbying
From the quarterly LD-2 filings at the U.S. Senate — a different register, and a different kind of fact.
This is not a trade and it is not scored. A lobbying filing says who lobbied for whom, on which issues, and for how much — it says nothing about the share price and nothing about this company’s insiders. The link between the client names in that register and TAKEDA PHARMACEUTICAL CO LTD is a reviewed rule of ours: an LD-2 names a client and carries no ticker, no CIK and no LEI.
Lobbying reported per quarter
reported amounts per quarter, latest version of each report
Reported income: what lobbying firms reported receiving from this company's clients, per quarter.